Clik here to view.
Roche Reports Positive Study of RoACTEMRA
Roche announced that the SUMMACTA study met its primary endpoint. Data from SUMMACTA will be submitted for presentation at an upcoming medical meeting.
View ArticleRoche Abandons Dalcetrapib Trial
Disappointing phase-III trial results have led Roche to discontinue all dalcetrapib studies.
View ArticleClik here to view.
Schizophrenia Drug Trial Shows Positive Results
Lundbeck and Otsuka have announced successful results from a Phase 3 clinical trial evaluating the efficacy, safety and tolerability of a once-monthly drug for the treatment of schizophrenia.
View ArticleClik here to view.
Study Focuses on Curcumin to Treat Cancer
Scientists will investigate whether tablets containing curcumin, a compound found in the spice turmeric, can be safely added to the standard treatment for bowel cancer that has spread.
View ArticleMucosis Announces Positive Proof-Of-Concept Data for Mimopath Platform In Humans
Mucosis, in conjunction with the Centre for Human Drug Research, conducted the clinical trial to assess the safety, tolerability, and immunogenicity of nasally administered FluGEM.
View ArticleClik here to view.
Novavax Launches Enrolment in Early-stage Trial of Bird Flu Vaccine
Novavax is enrolling patients in a second Phase 1 clinical trial of a vaccine that could prevent a potential bird flu pandemic.
View ArticlePharma Consortium Provides £14.4M Funding for Drug Discovery
The DSTT consortium has attracted new investment which will enable its vital drug discovery work to continue until at least 2016.
View ArticleLicensing And Co-development Deals 'Bridge Gap' to Drug Commercialisation
A report by consulting firm Cutting Edge Information has underlined the benefits of licensing and co-development deals.
View ArticleClik here to view.
BMS & Tsinghua Enter Drug Discovery Partnership
Bristol-Myers Squibb will fund research efforts at Tsinghua University's School of Life Sciences to identify and validate novel targets in oncology and immunoscience.
View ArticleElexoPharm Receives EUROSTARS Grant for Program Targeting Mitochondrial Diseases
This grant will support an ambitious scientific collaboration to discover treatments for mitochondrial diseases with high unmet medical need.
View ArticleClik here to view.
Boehringer Ingelheim Announces First Data for Tiotropium Study
Boehringer Ingelheim has announced results from a Phase II study evaluating the investigational compound tiotropium.
View ArticleLundbeck & CHDI Foundation Announce Research Collaboration
The collaboration aims to investigate a targeted therapy for Huntington’s disease.
View ArticleClik here to view.
IMI Launches Project on Antimicrobials
The Innovative Medicines Initiative launches a €223.7m programme aimed at tackling antibiotic resistance issue.
View ArticlePharmaceutical Giants Join Public-private Collaboration to Find Antibiotics
A new public-private collaboration aimed at discovering antibiotics has been welcomed by the industry.
View ArticleClik here to view.
Eli Lilly Opens Diabetes Research Center in China
The diabetes-specific R&D center, holding 150 scientists and staff when full, is part of a trend in drug development.
View ArticleClik here to view.
Janssen Submits NDA for Canagliflozin
The filing is supported by a comprehensive global Phase 3 clinical development program.
View ArticleClik here to view.
Lundbeck's Investigational Compound Meets Primary Endpoint
The study was conducted in 278 patients suffering from moderate Alzheimer’s disease, and Lu AE58054 was administered as add-on to donepezil, a commonly used acetylcholinesterase inhibitor for a period...
View ArticleClik here to view.
Genzyme Reports Positive Results of TOWER Trial
In the study, patients receiving teriflunomide 14 mg had a statistically significant reduction in annualized relapse rate and risk of sustained accumulation of disability.
View ArticleLophius Biosciences Completes Two Important Regulatory Milestones
Lophius Biosciences has announced the successful realization of two important regulatory milestones.
View ArticleAntisense Pharma Presents Trabedersen Phase I/II Complete Data at ASCO
Antisense Pharma has presented trabedersen complete data from its clinical Phase I/II study in patients with advanced pancreatic cancer, malignant melanoma or colorectal cancer.
View Article
